We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko and Trikafta, and development-stage product candidates. Royalty Pharma plc is based in NEW YORK.
- Recent RPRX Stock Price: $39.05
- Yearly Gain for RPRX stock: 1.08%
- Market Cap for RPRX stock: $23.91B
- P/E Ratio for RPRX stock: 33.927
Will RPRX's stock price go up? Is there an accurate RPRX stock forecast available?
TipRanks.com reports that Royalty Pharma currently has 6 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $52.33. The target pricing ranges from a high RPRX forecast of $60.00 down to a low forecast of $47.00. Royalty Pharma (RPRX)’s last closing stock price was $39.05 which would put the average price target at 34.01% upside.
In addition, TradingView issued a Strong Sell rating for RPRX stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on RPRX stock.
Other analysts covering RPRX include:
- Terence Flynn of Morgan Stanley issued a Buy rating with the price target of $ 51 on 1 month ago
- Chris Shibutani of Goldman Sachs issued a Buy rating with the price target of $ 60 on 2 months ago
- Ashwani Verma of UBS issued a Buy rating with the price target of $ 51 on 2 months ago
- Unknown Analyst of Truist Financial issued a Buy rating with the price target of $ 53 on 2 months ago
If you are wondering if RPRX is a good stock to buy, here are 3rd party ratings for RPRX stock:
- TipRanks.com: Strong Buy
- TradingView.com: Strong Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Bottom 45% (139 out of 251)
What is the sentiment on the street regarding Royalty Pharma? (Current ratings compiled by TipRanks.com)
- News Sentiment for RPRX stock: Very Bullish
- Blogger Consensus for RPRX stock: Bullish
- Media Buzz for RPRX stock: High
- Insider Signal for RPRX stock: Negative
- Investor Sentiment for RPRX stock: Positive
- Hedge Fund signal for RPRX stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on RPRX stock including scouring the social networks like RPRX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RPRX stock chart >>
Summary: Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.
- Recent ARWR Stock Price: $36.79
- Yearly Gain for ARWR stock: -36.31%
- Market Cap for ARWR stock: $3.90B
- P/E Ratio for ARWR stock: -21.933
Will ARWR's stock price go up? Is there an accurate ARWR stock forecast available?
TipRanks.com reports that Arrowhead Pharmaceuticals currently has 9 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $61.11. The target pricing ranges from a high ARWR forecast of $90.00 down to a low forecast of $31.00. Arrowhead Pharmaceuticals (ARWR)’s last closing stock price was $36.79 which would put the average price target at 66.10% upside.
In addition, TradingView issued a n/a (possibly response change) rating for ARWR stock over the next month, Barchart.com has a hold rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ARWR stock.
Other analysts covering ARWR include:
- Keay Nakae of Chardan Capital issued a Buy rating with the price target of $ 60 on 1 week ago
- Edward Tenthoff of Piper Sandler issued a Buy rating with the price target of $ 55 on 1 week ago
- Mayank Mamtani of B.Riley Financial issued a Buy rating with the price target of $ 59 on 1 week ago
- Luca Issi of RBC Capital issued a Buy rating with the price target of $ 83 on 1 week ago
If you are wondering if ARWR is a good stock to buy, here are 3rd party ratings for ARWR stock:
- TipRanks.com: Strong Buy
- TradingView.com: n/a (possibly response change)
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: hold
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding Arrowhead Pharmaceuticals? (Current ratings compiled by TipRanks.com)
- News Sentiment for ARWR stock: Very Bullish
- Blogger Consensus for ARWR stock: Bullish
- Media Buzz for ARWR stock: Medium
- Insider Signal for ARWR stock: Positive
- Investor Sentiment for ARWR stock: Very Positive
- Hedge Fund signal for ARWR stock: Positive
The stock market is extremely volatile, and you need to do your own research on ARWR stock including scouring the social networks like ARWR StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ARWR stock chart >>
Summary: Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo.
- Recent VRDN Stock Price: $36.97
- Yearly Gain for VRDN stock: 81.15%
- Market Cap for VRDN stock: $1.46B
- P/E Ratio for VRDN stock: -8.602
Will VRDN's stock price go up? Is there an accurate VRDN stock forecast available?
TipRanks.com reports that Viridian Therapeutics currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $45.73. The target pricing ranges from a high VRDN forecast of $62.00 down to a low forecast of $35.00. Viridian Therapeutics (VRDN)’s last closing stock price was $36.97 which would put the average price target at 23.69% upside.
In addition, TradingView issued a Buy rating for VRDN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on VRDN stock.
Other analysts covering VRDN include:
- Michael Higgins of Ladenburg Thalmann & Co. issued a Buy rating with the price target of $ 40 on 1 week ago
- Kalpit Patel of B.Riley Financial issued a Buy rating with the price target of $ 46 on 1 week ago
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $ 45 on 1 week ago
- Douglas Tsao of H.C. Wainwright issued a Buy rating with the price target of $ 35 on 1 week ago
If you are wondering if VRDN is a good stock to buy, here are 3rd party ratings for VRDN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Sell, Top 27% (69 out of 251)
What is the sentiment on the street regarding Viridian Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for VRDN stock: Very Bullish
- Blogger Consensus for VRDN stock: Bullish
- Media Buzz for VRDN stock: Very High
- Insider Signal for VRDN stock: ―
- Investor Sentiment for VRDN stock: Very Positive
- Hedge Fund signal for VRDN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on VRDN stock including scouring the social networks like VRDN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for VRDN stock chart >>
Summary: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies. The company's pipeline of product candidate involved in development for the treatment of haematological malignancies and solid tumours. Autolus Therapeutics plc is based in London, United Kingdom.
- Recent AUTL Stock Price: $1.98
- Yearly Gain for AUTL stock: -52.38%
- Market Cap for AUTL stock: $363.42M
- P/E Ratio for AUTL stock: -1.168
Will AUTL's stock price go up? Is there an accurate AUTL stock forecast available?
TipRanks.com reports that Autolus Therapeutics currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $10.33. The target pricing ranges from a high AUTL forecast of $18.00 down to a low forecast of $6.00. Autolus Therapeutics (AUTL)’s last closing stock price was $1.98 which would put the average price target at 421.72% upside.
In addition, TradingView issued a Sell rating for AUTL stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on AUTL stock.
Other analysts covering AUTL include:
- Asthika Goonewardene of Truist Financial issued a Buy rating with the price target of $ 6 on 1 week ago
- Gil Blum of Needham issued a Buy rating with the price target of $ 7 on 1 month ago
- Robert Burns of H.C. Wainwright issued a Buy rating with the price target of $ 11 on 3 months ago
- Unknown Analyst of Wells Fargo issued a Buy rating with the price target of $ 8 on 3 months ago
If you are wondering if AUTL is a good stock to buy, here are 3rd party ratings for AUTL stock:
- TipRanks.com: Strong Buy
- TradingView.com: Sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Buy, Top 27% (69 out of 251)
What is the sentiment on the street regarding Autolus Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for AUTL stock: Very Bullish
- Blogger Consensus for AUTL stock: Bullish
- Media Buzz for AUTL stock: High
- Insider Signal for AUTL stock: ―
- Investor Sentiment for AUTL stock: Very Positive
- Hedge Fund signal for AUTL stock: Neutral
The stock market is extremely volatile, and you need to do your own research on AUTL stock including scouring the social networks like AUTL StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AUTL stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================